Hsiao Liang-Tsai, Chung Hung-Ming, Lin Jen-Tsun, Chiou Tzeon-Jye, Liu Jin-Hwang, Fan Frank S, Wang Wei-Shu, Yen Chueh-Chuan, Chen Po-Min
Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan.
Br J Haematol. 2002 Jun;117(3):620-2. doi: 10.1046/j.1365-2141.2002.03499.x.
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
据报道，接受特异性酪氨酸激酶抑制剂STI571治疗的患者中有7%至21%会出现轻度至中度的皮肤不良反应。我们报告了一名慢性髓性白血病急变期患者，在接受STI571治疗1周后出现了危及生命的皮肤反应——史蒂文斯-约翰逊综合征。本报告可能有助于提醒临床医生，在未来更广泛地应用该药物之前，要注意STI571可能产生的严重皮肤副作用。
